Printer Friendly

MEDIMMUNE AND CYANAMID SIGN FOUR DRUG, $30 MILLION STRATEGIC ALLIANCE; MEDIMMUNE AND CYANAMID TO BEGIN SELLING ZOSYN TODAY

 GAITHERSBURG, Md., Nov. 9 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI), today announced it signed definitive agreements with American Cyanamid Company (NYSE: ACY) forming an alliance in the United States for the development and marketing of three generations of products for respiratory syncytial virus (RSV) and for the marketing of a new anti-infective product, Zosyn(TM), developed by Cyanamid. The alliance involves Cyanamid and its Lederle Laboratories and Lederle Praxis Biologicals divisions. MedImmune has previously announced on July 14, 1993, the signing of a letter of intent with Cyanamid.
 Under the terms of the agreements, MedImmune and Cyanamid will collaborate on the following products for RSV: (i) RespiGam(TM) (formerly Respivir(TM)), a polyclonal antibody product developed by MedImmune and currently under review for marketing approval by the U.S. Food and Drug Administration (FDA), and (ii) a second generation monoclonal antibody product being developed by MedImmune. The third product included in the alliance is Zosyn, an anti-infective developed by Cyanamid's Lederle Laboratories division for hospital use to treat serious infections. Zosyn was approved for marketing on Oct. 22, 1993. MedImmune and Cyanamid expect to commence sales of Zosyn today. Finally, MedImmune has an option to collaborate on an RSV vaccine being developed by Cyanamid's Lederle Praxis Biologicals division. In addition to co-promoting these four products, MedImmune will receive up to $30 million in funding from Cyanamid over five years.
 "Lederle's strong franchise within the U.S. pediatric pharmaceutical marketplace will help us maximize the value of RespiGam and build a long-term franchise in the prevention and treatment of RSV disease," commented Wayne T. Hockmeyer, Ph.D., chairman and chief executive officer. "In addition, the marketing alliance on Zosyn demonstrates our commitment to building our hospital sales force and an infectious disease franchise within the hospital."
 RSV is the leading cause of pneumonia and bronchiolitis in infants. Severe RSV disease occurs most frequently in children under the age of 2. More than 91,000 hospitalizations and 4,500 deaths occur each year in the United States as a result of RSV infecting in children. Children with pre-existing conditions, including lung or heart disease, prematurity or immunosuppression, are at significantly increased risk for severe disease and death from RSV. No product is currently licensed for prevention of RSV infection in the United States.
 Zosyn is a combination of piperacillin, a semisynthetic penicillin, and tazobactam, a beta-lactamase inhibitor, developed by Lederle as a broad spet?rum anti-infective. Zosyn is indicated as presumptive therapy before the specific cause of an infection has been identified, in the following infections caused by susceptible organisms: intra- abdominal infections (e.g., appendicitis complicated by rupture or abscess; peritonitis), community-acquired pneumonia, skin and skin structure infections (e.g., cellulitis, cutaneous abscess, ischemic diabetic foot infection) and gynecologic infections (e.g., post-partum endometritis, pelvic inflammatory disease).
 Edward V. Fritzky, president of the Lederle Laboratories division of Cyanamid commented that: "Lederle is excited about working with MedImmune to develop a series of products to prevent and treat RSV disease in children. There is a significant need for new products for RSV and we believe that combining the marketing, scientific and medical strengths of MedImmune and Lederle in this field will make for a very strong partnership."
 The alliance involves co-promoting RespiGam in the United States and co-developing and co-promoting the second generation monoclonal antibody product for RSV in the United States. In addition, MedImmune has an option to co-develop and co-promote Lederle Praxis Biologicals' RSV vaccine which is in clinical trials. MedImmune would detail the RSV products directly to hospitals through its own sales force, while Lederle's pediatric office and hospital sales forces of more than 1,000 representatives would detail to pediatricians and hospitals. The alliance also incudes co-promotion of Lederle's Zosyn which MedImmune will detail through its hospital sales force.
 Cyanamid, through its Lederle Laboratories and Lederle-Praxis Biologicals divisions, is a leader in the United States in the research, development and marketing of pharmaceuticals and vaccines to the pediatrician. In addition, through Lederle-Praxis Biologicals, Cyanamid has long term commitment to the development of a vaccine for RSV disease.
 Cyanamid is a research-based life sciences and chemical company which discovers and develops medical, agricultural and chemical products and manufactures and markets them in more than 135 countries.
 MedImmune, Inc., was formed in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of certain infectious diseases and cancers. MedImmune's corporate headquarters are in Gaithersburg.
 -0- 11/9/93
 /CONTACT: David M. Mott, vice president, business development and planning of MedImmune, 301-417-0770; or Rhonda Chiger of Noonan/Russo Communications, Inc. 212-696-4455, ext. 207/
 (MEDI ACY)


CO: MedImmune, Inc.; American Cyanamid Company ST: Maryland IN: MTC SU:

TW -- NY047 -- 3622 11/09/93 11:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1993
Words:787
Previous Article:ZOOM/FAXMODEM 14.4X EDITOR'S CHOICE IN UNITED KINGDOM
Next Article:DION ENTERTAINMENT ANNOUNCES ACQUISITION OF INTEREST IN LOUISIANA INDIAN GAMING CASINO AND KANSAS CLASS II FACILITY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters